Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Amacing
1. AMACING TRIAL( 2016)
eGFR of 30–59
eGFR of 30–59
328
332
Prophylactic hydration to protect renal function from intravascular iodinated
contrast material in patients at high risk of contrast-induced nephropathy (AMACING):
a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
Estelle C Nijssen et al.
2. AMACING TRIAL( 2016)
eGFR of 30–59
eGFR of 30–59
0.9%
NACL
328
332
Mean 1637 mL
Prophylactic hydration to protect renal function from intravascular iodinated
contrast material in patients at high risk of contrast-induced nephropathy (AMACING):
a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
Estelle C Nijssen et al.
3. AMACING TRIAL( 2016)
eGFR of 30–59
eGFR of 30–59
0.9%
NACL
328
332
Mean 1637 mL
Mean
dye load
91 mL
Prophylactic hydration to protect renal function from intravascular iodinated
contrast material in patients at high risk of contrast-induced nephropathy (AMACING):
a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
Estelle C Nijssen et al.
4. AMACING TRIAL( 2016)
eGFR of 30–59
eGFR of 30–59
0.9%
NACL
328
332
CIN=2.7%
Mean total costs/pt €1455
(US $1535)
5.5% complications
(4.0% CHF, 1.2% arrhythmias,
0.3% natremias)
CIN=2.6%
Mean total costs/pt €792
(US $835)
0% complications
Mean 1637 mL
Mean
dye load
91 mL
Prophylactic hydration to protect renal function from intravascular iodinated
contrast material in patients at high risk of contrast-induced nephropathy (AMACING):
a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
Estelle C Nijssen et al.
5. AMACING TRIAL( 2016)
eGFR of 30–59
eGFR of 30–59
0.9%
NACL
328
332
CIN=2.7%
Mean total costs/pt €1455
(US $1535)
5.5% complications
(4.0% CHF, 1.2% arrhythmias,
0.3% natremias)
CIN=2.6%
Mean total costs/pt €792
(US $835)
0% complications
Mean 1637 mL
Mean
dye load
91 mL
Prophylactic hydration to protect renal function from intravascular iodinated
contrast material in patients at high risk of contrast-induced nephropathy (AMACING):
a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
Estelle C Nijssen et al.